RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Castle Biosciences Stock

Castle Biosciences EBIT 2024

Castle Biosciences EBIT

-30.66 M USD

Ticker

CSTL

ISIN

US14843C1053

WKN

A2PNH3

In 2024, Castle Biosciences's EBIT was -30.66 M USD, a -54.89% increase from the -67.98 M USD EBIT recorded in the previous year.

The Castle Biosciences EBIT history

YEAREBIT (undefined USD)
2029e-
2028e6.12
2027e-13.26
2026e-49.79
2025e-73.87
2024e-30.66
2023-67.98
2022-91.2
2021-40.1
2020-6.5
20197.3
2018-3.8
2017-10.9

Castle Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Castle Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Castle Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Castle Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Castle Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Castle Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Castle Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Castle Biosciences’s growth potential.

Castle Biosciences Revenue, EBIT and net profit per share

DateCastle Biosciences RevenueCastle Biosciences EBITCastle Biosciences Net Income
2029e384.44 M undefined0 undefined6.51 M undefined
2028e366.13 M undefined6.12 M undefined8.91 M undefined
2027e331.96 M undefined-13.26 M undefined-6.93 M undefined
2026e304.91 M undefined-49.79 M undefined-40.91 M undefined
2025e265.18 M undefined-73.87 M undefined-65.56 M undefined
2024e302.58 M undefined-30.66 M undefined-16.6 M undefined
2023219.79 M undefined-67.98 M undefined-57.47 M undefined
2022137 M undefined-91.2 M undefined-67.1 M undefined
202194.1 M undefined-40.1 M undefined-31.3 M undefined
202062.6 M undefined-6.5 M undefined-10.3 M undefined
201951.9 M undefined7.3 M undefined3 M undefined
201822.8 M undefined-3.8 M undefined-10.2 M undefined
201713.8 M undefined-10.9 M undefined-15.3 M undefined

Castle Biosciences stock margins

The Castle Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Castle Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Castle Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Castle Biosciences's sales revenue. A higher gross margin percentage indicates that the Castle Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Castle Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Castle Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Castle Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Castle Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Castle Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Castle Biosciences Margin History

Castle Biosciences Gross marginCastle Biosciences Profit marginCastle Biosciences EBIT marginCastle Biosciences Profit margin
2029e79.53 %0 %1.69 %
2028e79.53 %1.67 %2.43 %
2027e79.53 %-3.99 %-2.09 %
2026e79.53 %-16.33 %-13.42 %
2025e79.53 %-27.86 %-24.72 %
2024e79.53 %-10.13 %-5.49 %
202379.53 %-30.93 %-26.15 %
202276.64 %-66.57 %-48.98 %
202183.21 %-42.61 %-33.26 %
202084.66 %-10.38 %-16.45 %
201985.93 %14.07 %5.78 %
201876.75 %-16.67 %-44.74 %
201763.77 %-78.99 %-110.87 %

Castle Biosciences Aktienanalyse

What does Castle Biosciences do?

Castle Biosciences Inc is an American company that was founded in 2007. The company's goal is to develop and distribute innovative diagnostic tests for various types of cancer. Castle Biosciences is headquartered in Friendswood, Texas, and has numerous branches throughout North America. The company currently has around 200 employees and a strong management team. The business model of Castle Biosciences is based on the development and marketing of personalized medical tests that can help improve the diagnosis and treatment of cancer patients. Castle Biosciences primarily offers its tests through doctors and medical facilities. The company specializes in the development of prognostic and predictive tests that can provide doctors with important information to create personalized treatment plans for their patients. Castle Biosciences has several divisions specializing in different types of cancer. One of the most important divisions is in the field of dermatology, developing and distributing tests for the diagnosis and prognosis of melanoma and other skin cancer types. Castle Biosciences also offers personalized tests for cancer of the eyes, stomach, and lung. Another important product of Castle Biosciences is the DecisionDx-Melanoma test. The test is a molecular diagnostic procedure that predicts the likelihood of melanoma recurrence. The test utilizes proprietary gene expression analysis to assess the risk of melanoma recurrence within five years after tumor removal. The results of the test can help minimize the risk of relapse and improve the patients' quality of life. Castle Biosciences has also developed the DecisionDx-UM test, a diagnostic test for uveal melanoma, a rare cancer affecting the eyes. The DecisionDx-UM test uses RNA expression to predict the individual metastatic risk of the cancer and support optimal medical management. The company has also specialized in the development of tests for gastric cancer. The CastleTest™ analyzes the transcription activity of 11 genes to determine the risk of tumor spread from the primary gastric location. Castle Biosciences has made significant progress in recent years and continues to expand through the introduction of new products and services in the market. The company emphasizes a certification program and continuous training of doctors and pathologists to support test performance. Additionally, Castle Biosciences has brought together additional knowledge and expertise through partnerships with other companies and institutions to develop innovative solutions for a wider range of cancer types. Overall, Castle Biosciences is a company specializing in innovative solutions for the diagnosis and prognosis of cancer. The personalized tests from Castle Biosciences have the potential to improve the quality of life for cancer patients by providing additional information for individual treatment plans. With its dedicated workforce and successful products, Castle Biosciences will continue to play an important role in the fight against cancer. Castle Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Castle Biosciences's EBIT

Castle Biosciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Castle Biosciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Castle Biosciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Castle Biosciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Castle Biosciences stock

How much did Castle Biosciences achieve in EBIT for the current year?

In the current year, Castle Biosciences has achieved an EBIT of -30.66 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Castle Biosciences.

How has the EBIT of Castle Biosciences developed in recent years?

The EBIT of Castle Biosciences has increased by -54.894% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Castle Biosciences?

The EBIT of Castle Biosciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Castle Biosciences pay?

Over the past 12 months, Castle Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Castle Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Castle Biosciences?

The current dividend yield of Castle Biosciences is .

When does Castle Biosciences pay dividends?

Castle Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Castle Biosciences?

Castle Biosciences paid dividends every year for the past 0 years.

What is the dividend of Castle Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Castle Biosciences located?

Castle Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Castle Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Castle Biosciences from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Castle Biosciences pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Castle Biosciences in the year 2023?

In the year 2023, Castle Biosciences distributed 0 USD as dividends.

In which currency does Castle Biosciences pay out the dividend?

The dividends of Castle Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Castle Biosciences

Our stock analysis for Castle Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Castle Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.